| Indicators | Browse All

Sol-Gel Technologies Ltd. (SLGL)

Healthcare | Biotechnology | Ness Ziona, Israel | NasdaqCM
68.30 USD -4.10 (-5.663%) ⇩ (Oct. 13, 2026, 4 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take ↕ | Oct. 10, 2026, 1:31 a.m. EDT

The immediate outlook is severely compromised by a catastrophic collapse in business fundamentals. Revenue has plummeted by nearly 97% year-over-year, while the company burns through significant operating cash and reports negative free cash flow. Despite a 'strong buy' recommendation from analysts and a high price target, these opinions appear disconnected from the reality of a shrinking top line and deteriorating margins. The recent capital raise suggests a desperate need for liquidity rather than organic growth strength. With no dividend to provide income and a balance sheet showing negative returns on both assets and equity, there is no defensive floor for investors. The statistical forecast models also indicate a slight downward bias, though their low reliability makes them secondary to the glaring operational decline. This is a high-risk speculative vehicle where the thesis relies entirely on a future turnaround that has not yet materialized in the financials.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.120428
MSTL0.123962
AutoTheta0.200799
AutoARIMA0.227199

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 28%
H-stat 22.55
Ljung-Box p 0.000
Jarque-Bera p 0.181
Excess Kurtosis -1.23
Attribute Value
Sector Healthcare
Debt to Equity Ratio 1.601
Revenue per Share 0.615
Market Cap 223,614,144
Forward P/E -8.17
Beta 1.15
Website https://www.sol-gel.com

Info Dump

Attribute Value
52 Week Change 0.8213836
Address1 7 Golda Meir Street
Address2 Weizmann Science Park
All Time High 210.0
All Time Low 3.34
Ask 72.86
Ask Size 2
Average Analyst Rating 1.0 - Strong Buy
Average Daily Volume10 Day 35,310
Average Daily Volume3 Month 55,287
Average Volume 55,287
Average Volume10Days 35,310
Beta 1.15
Bid 71.13
Bid Size 2
Book Value 14.69
City Ness Ziona
Compensation As Of Epoch Date 1,767,139,200
Country Israel
Crypto Tradeable 0
Currency USD
Current Price 68.3
Current Ratio 10.368
Custom Price Alert Confidence HIGH
Date Short Interest 1,790,726,400
Day High 72.805
Day Low 68.3
Debt To Equity 1.601
Display Name Sol-Gel
Dividend Yield 0.0
Earnings Timestamp 1,787,229,000
Earnings Timestamp End 1,795,091,400
Earnings Timestamp Start 1,795,091,400
Ebitda -17,690,000
Ebitda Margins 0.0
Enterprise To Ebitda -9.975
Enterprise To Revenue 98.304
Enterprise Value 176,455,136
Eps Current Year -8.73
Eps Forward -8.35667
Eps Trailing Twelve Months -5.61
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 15
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 73.1283
Fifty Day Average Change -4.8283005
Fifty Day Average Change Percent -0.066025056
Fifty Two Week Change Percent 82.13836
Fifty Two Week High 97.97
Fifty Two Week High Change -29.669998
Fifty Two Week High Change Percent -0.3028478
Fifty Two Week Low 28.81
Fifty Two Week Low Change 39.490005
Fifty Two Week Low Change Percent 1.3707049
Fifty Two Week Range 28.81 - 97.97
Financial Currency USD
First Trade Date Milliseconds 1,517,495,400,000
Float Shares 489,004
Forward Eps -8.35667
Forward P E -8.173112
Free Cashflow -2,120,250
Full Exchange Name NasdaqCM
Full Time Employees 28
Fullday Change -4.0999985
Fullday Change Percent -5.59574
Fullday Price 68.3
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -14,025,000
Has Pre Post Market Data 1
Held Percent Insiders 0.59657
Held Percent Institutions 0.43058
Implied Shares Outstanding 3,273,999
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,746,403,200
Last Split Factor 1:10
Long Business Summary Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Long Name Sol-Gel Technologies Ltd.
Market us_market
Market Cap 223,614,144
Market State POSTPOST
Max Age 86,400
Message Board Id finmb_621569
Most Recent Quarter 1,782,777,600
Net Income To Common -16,337,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 197,356,659
Number Of Analyst Opinions 2
Open 72.805
Operating Cashflow -8,542,000
Operating Margins -7.0422997
Payout Ratio 0.0
Phone 972 8 931 3433
Previous Close 72.4
Price Eps Current Year -7.8235974
Price Hint 2
Price To Book 4.6494217
Price To Sales Trailing12 Months 124.576126
Profit Margins 0.0
Quick Ratio 9.873
Quote Source Name Delayed Quote
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.0
Region US
Regular Market Change -4.1
Regular Market Change Percent -5.66298
Regular Market Day High 72.805
Regular Market Day Low 68.3
Regular Market Day Range 68.3 - 72.805
Regular Market Open 72.805
Regular Market Previous Close 72.4
Regular Market Price 68.3
Regular Market Time 1,791,921,600
Regular Market Volume 33,736
Return On Assets -0.23868
Return On Equity -0.40854
Revenue Growth -0.966
Revenue Per Share 0.615
Sand P52 Week Change 0.17502642
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 3,273,999
Shares Percent Shares Out 0.044499997
Shares Short 145,819
Shares Short Previous Month Date 1,788,134,400
Shares Short Prior Month 74,053
Short Name Sol-Gel Technologies Ltd.
Short Percent Of Float 0.1378
Short Ratio 2.55
Source Interval 15
Symbol SLGL
Target High Price 195.0
Target Low Price 110.0
Target Mean Price 152.5
Target Median Price 152.5
Total Cash 47,929,000
Total Cash Per Share 14.639
Total Debt 770,000
Total Revenue 1,795,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -5.61
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 72.83364
Two Hundred Day Average Change -4.533638
Two Hundred Day Average Change Percent -0.062246483
Type Disp Equity
Volume 33,736
Website https://www.sol-gel.com
Zip 7,403,650